Article
MDM2 rs2279744 and TP53 rs1042522 polymorphisms associated with etoposide- and cisplatin-induced grade III/IV neutropenia in Chinese extensive-stage small-cell lung cancer patients.
Oncology research and treatment - 1 Jan 2014
Wang Xu, Wang Yi-Zhuo, Ma Ke-Wei, Chen Xiao, Li Wei
Abstract excerpt
BACKGROUND/AIMS: Etoposide and cisplatin (EP) chemotherapy is the most frequently used regimen in extensive-stage small-cell lung cancer (SCLC) patients, although the side effects (e.g., neutropenia) are high. This study investigates the association of the MDM2 rs2279744 and TP53 rs1042522 single...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.